{"entity":{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","aka":[],"tldr":"Published report from the CYPIDES trial registered as NCT03436485, in NEJM Evidence (2024), chosen as the most cited paper whose own text cites the registry id.","summary":"BACKGROUND: Prostate cancer is regulated by steroid hormones, even in castration-resistant disease. ODM-208, a novel inhibitor of cytochrome P450 11A1 (which catalyzes the first step of steroid-hormone biosynthesis), was investigated in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). METHODS: CYPIDES is a first-in-human phase 1 (3 + 3 design) and phase 2 study. We administered ODM-208 twice daily with glucocorticoid/mineralocorticoid replacement and ongoing androgen deprivation therapy to adults with previously treated mCRPC, regardless of androgen receptor gene (AR) ligand-binding domain mutations (phase 1) and with activating AR ligand-binding domain mutations (ARmut; phase 2). Safety, pharmacokinetics, steroid-hormone pharmacodynamics, and preliminary efficacy were the key outcomes. RESULTS: Ninety-two patients received one or more doses of ODM-208: 47 in phase 1 (20 [42.6%] with ARmut) and 45 in phase 2 (all ARmut). A dose of ODM-208 of 5 mg twice a day with dexamethasone 1 mg/fludrocortisone 0.1 mg provided a balance between decreased steroidogenesis and toxicity. Treatment-related adrenal insufficiency was the most common toxicity in phase 1 (n=17, 36.2%; necessitating ODM-208 discontinuation in one patient); this toxicity occurred in six patients (13.3%) at 5 mg twice a day in phase 2. Median circulating testosterone levels declined from 3.0 ng/dl (interquartile range, 1.3 to 6.2 ng/dl) at baseline to undetectable levels within the first week of ODM-208 5 mg twice a day treatment in 46 of 53 (87%) patients. A decrease in prostate-specific antigen levels of 50% or more occurred in 14 of 19 (73.7%) patients with ARmut and 2 of 23 (8.7%) patients with AR wild type in phase 1 and in 24 of 45 (53.3%) patients with ARmut in phase 2. CONCLUSIONS: ODM-208 potently inhibited steroid-hormone biosynthesis with the expected toxicity of adrenal insufficiency. Evidence of antitumor activity was observed in this heavily pretreated mCRPC population, especially in those with ARmut. (Funded by Orion Pharma; ClinicalTrials.gov number, NCT03436485.)\n\nIndexed on Europe PMC as PubMed record 38320513 (DOI 10.1056/evidoa2300171). Its abstract cites the registry id NCT03436485, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"NEJM Evid 2024","url":"https://doi.org/10.1056/evidoa2300171"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38320513/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/38320513"},{"label":"ClinicalTrials.gov NCT03436485","url":"https://clinicaltrials.gov/study/NCT03436485"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03436485"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm-evidence"],"dependsOn":[],"notes":[],"journal":"NEJM Evidence","year":2024,"doi":"10.1056/evidoa2300171","pmid":"38320513","authors":"Fizazi K, Bernard-Tessier A, Roubaud G, et al.","paperType":"observational","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT03436485 with the most citations, so it is the natural first reading for anyone following the CYPIDES trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct03436485-nejm-evid-2024/","neighbours":{"trial":[{"id":"nct03436485","kind":"trial","name":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct03436485/"}],"journal":[{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/"}]}}